Skip to main navigation Skip to search Skip to main content

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

  • Sehhoon Park
  • , Tae Min Kim
  • , Ji Youn Han
  • , Gyeong Won Lee
  • , Byoung Yong Shim
  • , Yun Gyoo Lee
  • , Sang We Kim
  • , Il Hwan Kim
  • , Suee Lee
  • , Yu Jung Kim
  • , Ji Hyun Park
  • , Sang Gon Park
  • , Ki Hyeong Lee
  • , Eun Joo Kang
  • , Ju Won Kim
  • , Seong Hoon Shin
  • , Chan Young Ock
  • , Byung Ho Nam
  • , Jaebong Lee
  • , Hyun Ae Jung
  • Jong Mu Sun, Se Hoon Lee, Jin Seok Ahn, Myung Ju Ahn
  • Seoul National University
  • National Cancer Center Korea
  • Gyeongsang National University
  • The Catholic University of Korea
  • Kangbuk Samsung Hospital
  • University of Ulsan
  • Inje University
  • Dong-A University
  • Konkuk University
  • Chosun University
  • Chungbuk National University
  • Korea University
  • Kosin University
  • Lunit, Inc.
  • HERINGS
  • Seoul

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science